Alpha Sense BI

APRIL 29, 2024

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

MAY 5, 2023

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 19, 2024

On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. As we navigate 2024, the landscape appears positioned for a triumphant comeback. Over the past few years, the technology industry has experienced dramatic highs and lows.

Technology 69

Technology Technology Retail Biotech 69